a year ago
AZN
AnalystsSteve ScalaSteve Scala's Stock Forecasts
AnalystsSteve Scala
Sectors:
Industries:
Analyst Ranking
Top 25%
#1246 out of 4929 analysts
Average Return
+11.48%
Win Rate
71%15 out of 21
Risk vs Reward
Poor
Good
Steve Scala's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Eli Lilly & CoLLY | +89.72% | $423.21 | $802.91 | 2023-05-23 - 2024-05-22 | Buy |
Eli Lilly & CoLLY | +58.60% | $369.29 | $585.68 | 2022-12-05 - 2023-12-04 | Buy |
Eli Lilly & CoLLY | +34.23% | $232.97 | $312.72 | 2021-06-24 - 2022-06-23 | Buy |
Eli Lilly & CoLLY | +22.98% | $151.18 | $185.92 | 2020-04-15 - 2021-04-15 | Buy |
Eli Lilly & CoLLY | +18.24% | $262.31 | $310.15 | 2021-08-30 - 2022-08-29 | Buy |
Steve Scala Analyst Color
Get additional color on Steve Scala's coverage of popular stocks
2 years ago
PFE
2 years ago
LLY
Steve Scala's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Abbvie IncABBV | 10 | Strong Buy | $225.00 | +18.87% | Maintains | 9 months ago |
Bristol Myers Squibb CoBMY | 3 | Hold | $59.00 | +25.75% | Maintains | 9 months ago |
Astrazeneca PLCAZN | 1 | Strong Buy | $95.00 | +36.79% | Maintains | a year ago |
Merck & Co IncMRK | 1 | Buy | $135.00 | N/A | Upgrades | 2 years ago |
Pfizer IncPFE | 1 | Hold | $32.00 | N/A | Downgrades | 2 years ago |
Roche Holding LtdRHHBY | 3 | Hold | $40.00 | N/A | Maintains | 2 years ago |
Eli Lilly & CoLLY | 6 | Buy | $500.00 | N/A | Maintains | 2 years ago |
Eqrx IncEQRX | 1 | Buy | N/A | N/A | Initiates Coverage On | 3 years ago |
Novartis AgNVS | 3 | Hold | $105.00 | N/A | Downgrades | 4 years ago |
Royalty Pharma PLCRPRX | 1 | Buy | $55.00 | N/A | Initiates Coverage On | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.